Vanguard Capital Management
PTHS

Vanguard Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

Vanguard Capital Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
97,134
+4,041
+4% +$104K ﹤0.01% 3316
2026
Q1 		$1.96M Buy
+93,093
New +$2.21M ﹤0.01% 3372

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.53% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's PTHS Position: Q2 2026 in Review

Vanguard Capital Management increased its Pelthos Therapeutics (PTHS) stake by 4.3% in Q2 2026, buying an estimated $104K and bringing the position to 97,134 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Vanguard Capital Management first reported a position in PTHS in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Vanguard Capital Management held 97,134 shares of Pelthos Therapeutics worth $2.75M as of Q2 2026.
  • Vanguard Capital Management bought 4,041 Pelthos Therapeutics shares in Q2 2026, an estimated $104K.
  • Pelthos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3316 holding.
  • Vanguard Capital Management first reported a position in Pelthos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.